Loading
A phase 3 trial of Pexidartinib in tenosynovial giant cell tumour, run by Daiichi Sankyo Co., Ltd., active and no longer recruiting.
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT is a phase 3 interventional study registered as NCT04488822 by Daiichi Sankyo Co., Ltd., with 40 participants enrolled, started 2020-09-25 and due to reach its primary completion in 2021-10-27. Interventions recorded: Pexidartinib. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
40 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2023-04-27), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) of Pexidartinib Based on RECIST 1.1 of Asian Participants With Symptomatic Tenosynovial Giant Cell Tumor (TGCT) at Week 25, ORRprimary | Pexidartinib | 40 | 9 participants | - | - | link |
Shares Daiichi Sankyo, Small-molecule kinase inhibitors and the tag pipeline.
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.